[{"id":"00668bbd-a5a7-4a9e-ac8c-d8cfd565ce2a","acronym":"14","url":"https://clinicaltrials.gov/study/NCT05909618","created_at":"2023-06-18T17:07:55.354Z","updated_at":"2024-07-02T16:35:27.854Z","phase":"Phase 2","brief_title":"Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases","source_id_and_acronym":"NCT05909618 - 14","lead_sponsor":"Sheba Medical Center","biomarkers":" BRAF • MGMT","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide • Adakveo (crizanlizumab-tmca)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 07/30/2028","primary_completion_date":" 07/30/2028","study_txt":" Completion: 07/30/2030","study_completion_date":" 07/30/2030","last_update_posted":"2023-11-28"}]